Completed PHASE1 INTERVENTIONAL NCT00213005

Safety and Acceptability of Carraguard® in HIV Positive Women and Men

A Phase 1 Safety and Acceptability Study of Carraguard® Among HIV Positive Women and Men in Durban, South Africa

Sponsor: Centers for Disease Control and Prevention

Updated 7 times since 2017 Last updated: Aug 11, 2017 Started: Jun 30, 2002 Completion: Aug 31, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00213005, this PHASE1 trial focuses on HIV Infections and remains completed. Sponsored by Centers for Disease Control and Prevention, it has been updated 7 times since 2002, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE1
Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Sep 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Sep 2017 [monthly]

Completed PHASE1

First recorded

Jun 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Centers for Disease Control and Prevention
Medical Research Council
Population Council

Data source: Population Council

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Durban, South Africa